Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05365243 Withdrawn - Breast Cancer Clinical Trials

A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads

Start date: August 15, 2022
Phase: N/A
Study type: Interventional

Eligible patients will be recruited prior to initiation of chemotherapy for any stage breast or gynecologic cancer. Patients will undergo training in the use of the AMMA Portable Scalp Cooling System and will use the device during each of their chemotherapy treatments. Quality of life and experience of use questionnaires will be completed. Scalp photos and an assessment of hair loss will be preformed at enrollment and at the end of study participation.

NCT ID: NCT05359874 Withdrawn - Breast Cancer Clinical Trials

Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW

DoT-FMI
Start date: June 2021
Phase: Phase 2
Study type: Interventional

It is a prospective, open, non-randomized, multicenter, one-armed, blinded (surgeon), diagnostic clinical trial according to AMG and MPG. The fluorescent marker Bevacizumab-IRDye800CW has advantages over conventional methods of tumor imaging in terms of accuracy, patient safety and validity. In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.

NCT ID: NCT05338281 Withdrawn - Breast Cancer Clinical Trials

NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT

NPWTinDIEP
Start date: September 2023
Phase: N/A
Study type: Interventional

The current study is a single center randomized control trial that will examine the effect of closed incision negative pressure wound therapy (ciNPT) versus conventional dressing on abdominal incision in a deep inferior epigastric perforator (DIEP) flap based reconstruction. Patients will be followed by 30 days post-operatively to compare outcomes including the rate of surgical site infection, seroma, and the scar quality.

NCT ID: NCT05301595 Withdrawn - Breast Cancer Clinical Trials

TAP vs QL for Postoperative Analgesia After DIEP Free Flap Breast Reconstruction

Start date: April 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of Transversus abdominus plane (TAP) block and Quadratus Lumborum (QL) block on the quality of recovery after breast reconstruction with deep inferior epigastric perforator (DIEP) flap.

NCT ID: NCT05263648 Withdrawn - Breast Cancer Clinical Trials

Virtual Reality Software to Reduce Stress in Cancer Patients

OU-SCC VR
Start date: September 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test the ability of virtual reality-based social support to increase patient adherence to radiation therapy by reducing patient distress.

NCT ID: NCT05245162 Withdrawn - Clinical trials for Breast Cancer Female

Fertility Changes Due to Cancer: an Investigation of Meaning, Psychological Distress, and Psychologi

Start date: January 11, 2021
Phase:
Study type: Observational

Establish the relationship between meaning and psychological distress in young women with breast cancer who experienced reproductive concerns due to cancer diagnosis and treatment and their partners.

NCT ID: NCT05191004 Withdrawn - Breast Cancer Clinical Trials

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant monotherapy. The study population is comprised of adults with HR+HER2- aBC. Patients will self-administer NUV-422 orally in 28-day cycles and receive 500 mg fulvestrant intramuscularly (IM) on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT05156463 Withdrawn - Breast Cancer Clinical Trials

The PAI Trial for Breast and Colon Cancer Survivors

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if a Physical Activity Index (PAI) tool that collects measures on physical activity, strength training and sedentary behavior can be used in a clinical setting to monitor patient behavior and provide specific recommendations on how to achieve and maintain behavior goals. The tool will be used after treatment is completed in breast and colon cancer survivors and will test if physician counseling combined with patient self-monitoring improves physical activity and reduces sedentary behavior over time.

NCT ID: NCT05041751 Withdrawn - Breast Carcinoma Clinical Trials

Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain Syndrome

Start date: March 23, 2022
Phase: N/A
Study type: Interventional

This clinical trial studies the effect of myofascial release in decreasing post-mastectomy pain compared to standard of care trigger point injections in patients with post-mastectomy pain syndrome. Patients who have mastectomies often experience pain that does not go away after time. This is known as post-mastectomy pain syndrome. Myofascial release is a form of physical therapy in which pressure is applied to the affected areas. Myofascial release may be an effective way of decreasing pain in patients with post-mastectomy pain syndrome without the use of medication.

NCT ID: NCT05039931 Withdrawn - Breast Cancer Clinical Trials

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.